Number of the records: 1

Pregnanolone derivatives substituted in 3alpha-position with the cationic group, usage and pharmaceutical preparation involving them

SYSNO ASEP	0500216
Document Type	P - Patent
R&D Document Type	Patent or other outcome protected by special legislation
Title	Pregnanolone derivatives substituted in 3alpha-position with the cationic group, usage and pharmaceutical preparation involving them
Author(s)	Chodounská, Hana (UOCHB-X)_{RID, ORCID} Kapras, Vojtěch (UOCHB-X) Vyklický ml., Ladislav (FGU-C)_{RID, ORCID, SAI} Borovská, Jiřina (UOCHB-X) Vyklický, Vojtěch (FGU-C)_{RID, ORCID, SAI} Valeš, Karel (FGU-C)_{RID, ORCID, SAI} Stuchlík, Aleš (FGU-C)_{RID, ORCID} Rambousek, Lukáš (FGU-C)_{RID, ORCID}
Year of issue	2018
Possible third party use of the result	A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence
Royalty requested	A - Poskytovatel licence požaduje licenční poplatek
Patent no. or utility model no. or industrial design no.	EP2675821
Date of the patent acceptance	18.04.2018
Name of the patent owner	Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i
Code of the issuer name	EPO_1 - European Patent Office Munich, The Hague, Berlin, Vienna, Brusselshttp://www.epo.org/
Current use	A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem
Language	eng - English
Keywords	pregnanolone derivatives ; CNS ; neuroactive steroids ; neuroprotectives
Subject RIV	CC - Organic Chemistry
OECD category	Organic chemistry
Institutional support	UOCHB-X - RVO:61388963 ; FGU-C - RVO:67985823
Annotation	The presented invention applies to pregnanolone derivatives, substituted in 3 alpha-position with the cationic group, of general formula I, the method of the production of these compounds and their utilization for treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post traumatic stress dissorder, and other diseases related to stress, anxiety, schizophrenia, and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy, and gliomas. The object of invention is also the use of compounds of general formula I for production of veterinary and human pharmaceutical preparation for treatment of above mentioned diseases and for production of pharmaceutical preparations containing these compounds.
Workplace	Institute of Organic Chemistry and Biochemistry
Contact	asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418
Year of Publishing	2019
Electronic address	https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180418&DB=&locale=en_EP&CC=EP&NR=2675821B1&KC=B1&ND=4#

Number of the records: 1